Bio­gen pressed against the wall as more stake­hold­ers side against Aduhelm; Prime time for CRISPR 3.0?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As the End­points team grows, we are find­ing more time to do in­ter­views un­der em­bar­goes and pur­sue more in-depth fea­tures — per­son­al­ly two of my fa­vorite parts of this job. Got news lined up in the near fu­ture? You can al­ways reach us at ed­i­to­r­i­al@end­pointsnews.com.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER